Author at Microdose

Elisabetta Fato

A native Italian, I currently study Biomedical Sciences at Queen Mary University of London. I have been closely following the latest updates in psychedelics research since the beginning of my undergraduate studies. My passion for science and writing allowed me to write articles published by the British Pharmacological Society and Neurosight, now available on their online magazine and blog respectively. In the future, I am determined to pursue a research career in Neuroscience and Neuropsychopharmacology for the study of Human Consciousness, and I truly believe in the potential of psychedelics as tools that could be used for the investigation of its nature.

Science

19 Jan 2023

New Study Shows Psilocybin Increases Music Pleasure in Depression Patients

New study showed a correlation between psilocybin treatments and increased level of music-evoked emotions in depression patients...

By Elisabetta Fato

Science

23 Nov 2022

New Study Shows Psychedelics Lowers Barriers to Higher Brain States

A recent study conducted by Cornell University has shown that psychedelics might lower the energy threshold brain networks require in order to shift to different configurations....

By Elisabetta Fato

Science

5 Oct 2022

New Study Shows Physical Healing Potential of Ayahuasca

A recent study showed the regenerative properties and wound healing of ayahuasca and were investigated in vitro....

By Elisabetta Fato

Industry, Science

7 Sep 2022

A Deeper Look at Ketamine for Alcohol Use Disorder

The psychedelic compound ketamine is gaining particular attention for the treatment of alcohol use disorder (AUD), with clinical studies being conducted to explore its potential....

By Elisabetta Fato

Join Our Newsletter for Exclusive Updates, Stories, and More

Science

21 Jul 2022

Science Feature: MindMed’s LSD Trial for ADHD

We take a deeper look at MindMed’s phase 2a trial using low doses of LSD for ADHD...

By Elisabetta Fato

Science

14 Jul 2022

Science Feature: Next-Generation Psychedelics

Next-generation psychedelics are compounds whose structure derives or is built upon classical psychedelics like DMT, LSD and psilocybin — yet changed by inserting modifications to reduce possible adverse effects....

By Elisabetta Fato

Science

1 Jul 2022

Science Feature: Can Psychedelics Help Cure Color-Blindness?

In a 2017 online survey, psychedelic users reported improved symptoms of color-blindness....

By Elisabetta Fato

Science

24 Jun 2022

Science Feature: Psychedelics for Neuro-degenerative Diseases

Psychedelics are gradually catching on in mental health therapeutics and captivating more and more researchers, it seems their mechanism of action could be exploited in other therapeutic fields, such as...

By Elisabetta Fato

Science

14 Jun 2022

Science Feature: A Look at MDMA for PTSD

The legalization and destigmatization of psychedelics are being increasingly encouraged and supported, especially by the community of war veterans, with studies and personal reports of their therapeutic effects on PTSD...

By Elisabetta Fato

Follow us on social

Latest News

You Might Also Like

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts

10 Oct 2025

After the Billion-Dollar Psychedelic Bet: Who’s Next for Big Pharma?

In the wake of Gilgamesh’s billion-dollar exit, a new wave of companies is emerging, smaller, stealthier, and far more scientifically disciplined than their first-wave predecessors. Their mission: harness the therapeutic...

By Madison Roberts

WordPress Ads